actin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
In contrast, 298Fl (predicted to lie within the region of maximum shell effects) may have a much longer spontaneous fission half-life, possibly on the order of 1019 years. In the center of the island, there may be competition between alpha decay and spontaneous fission, though the exact ratio is model-dependent. The alpha decay half-lives of 1700 nuclei with 100 ≤ Z ≤ 130 have been calculated in a quantum tunneling model with both experimental and theoretical alpha decay Q-values, and are in agreement with observed half-lives for some of the heaviest isotopes. The longest-lived nuclides are also predicted to lie on the beta-stability line, for beta decay is predicted to compete with the other decay modes near the predicted center of the island, especially for isotopes of elements 111–115. Unlike other decay modes predicted for these nuclides, beta decay does not change the mass number. Instead, a neutron is converted into a proton or vice versa, producing an adjacent isobar closer to the center of stability (the isobar with the lowest mass excess). For example, significant beta decay branches may exist in nuclides such as 291Fl and 291Nh; these nuclides have only a few more neutrons than known nuclides, and might decay via a "narrow pathway" towards the center of the island of stability. The possible role of beta decay is highly uncertain, as some isotopes of these elements (such as 290Fl and 293Mc) are predicted to have shorter partial half-lives for alpha decay.
=== Endosymbionts === The Oceanospirillales symbionts are found in the specialized roots of all Osedax species, and play a major role in accelerating the degradation process of bones, as well as facilitating nutrient uptake for the Osedax. Oceanospirillales are known for their ability to degrade complex organic compounds. Campylobacterales are abundant along the trunk of the Osedax according to a 2023 study. Different genera in this order are found in Osedax at different points during the whale's degradation:
Delta-beta thalassemia is a rare form of thalassemia in which there is a reduced production of hemoglobin subunit delta and hemoglobin subunit beta and raised levels of hemoglobin subunit gamma. It is an autosomal recessive disorder.
Sources: en.wikipedia.org
During Saddam Hussein's 2003–2004 interrogation following his capture he claimed that in addition to economic disputes, an insulting exchange between the Kuwaiti emir Al Sabah and the Iraqi foreign minister – during which the emir stated his intention to turn "every Iraqi woman into a $10 prostitute" by bankrupting the country – was a decisive factor in triggering the Iraqi invasion. On the 25th, Saddam met with April Glaspie, the US ambassador to Iraq, in Baghdad. The Iraqi leader attacked American policy with regards to Kuwait and the UAE:
Unlabeled antibody is incubated in the presence of its antigen (sample) A sufficient incubation period is provided to allow the antibodies to bind to the antigens. The sample is then passed through the Scavenger container. This can be a test tube or a specifically designed flow through channel. The surface of the Scavenger container or channel has "Scavenger Antigens" bound to it. These can be identical or sufficiently similar to the primary antigens that the free antibodies will bind. The Scavenger container must have sufficient surface area and sufficient time to allow the Scavenger Antigens to bind to all the excess Antibodies introduced into the sample. The sample, that now contains the tagged and bound antibodies, is passed through a detector. This device can be a flow cytometer or other device that illuminates the tags and registers the response. This test allows multiple antigens to be tagged and counted at the same time. This allows specific strains of bacteria to be identified by two (or more) different color tags. If both tags are present on a cell, then the cell is that specific strain. If only one is present, it is not. This test is done, generally, one test at a time and cannot be done with the microtiter plate. The equipment needed is usually less complicated and can be used in the field.
Trump was the subject of various criminal and civil legal proceedings before and during his 2024 re-election campaign. Specifically, Trump was found liable in a civil proceeding for financial fraud in 2023, was found liable for both sexual abuse and defamation in 2023, and was found liable for defamation in a related civil proceeding in 2024. In 2024, Trump was criminally convicted of 34 felonies related to falsifying business records. Trump and other Republicans made numerous false and misleading statements regarding Trump's various legal proceedings, including false claims that they were "rigged" or consisted of "election interference" orchestrated by Biden and the Democratic Party.
Sources: en.wikipedia.org
=== von Reumont et al. (2012) === In a 2012 molecular study, von Reumont et al. challenge the monophyly of Vericrustacea: they present four versions of Pancrustacea cladogram (figures 1–4), and in all four figures Remipedia is a sister group to Hexapoda, and Branchiopoda is a sister group to (Remipedia + Hexapoda). Thus, their data strongly suggest that Branchiopoda is more closely related to Hexapoda and Remipedia than to Multicrustacea. Based on these data, they propose the following scenario of evolution of Branchiopoda, Remipedia and Hexapoda: under the impact of predatory fishes their common ancestors go to the littoral zone, then ancestors of Branchiopoda go to the ephemeral freshwater habitat, whereas ancestors of Remipedia go to the anchialine cave, and ancestors of Hexapoda go to the land.
== Playing career == Player is one of the most successful golfers in history, tied for fourth in major championship victories with nine. Along with Arnold Palmer and Jack Nicklaus he is often referred to as one of "The Big Three" golfers of the mid-1960's. From the late 1950s through the late 1970s golf boomed in the United States and around the world and was greatly encouraged by expanded television coverage. Along with Gene Sarazen, Ben Hogan, Jack Nicklaus, Tiger Woods and Rory McIlroy, he is one of only six players to win golf's "career Grand Slam". He completed the Grand Slam in 1965 at the age of 29. At the time, he was the youngest player to do this, though Jack Nicklaus (26) and Tiger Woods (24) subsequently broke this record. Player was the second multiple majors winner from South Africa, following Bobby Locke, then was followed by Ernie Els, and Retief Goosen. Player competed regularly on the U.S. based PGA Tour from the late 1950s. He led the Tour money list in 1961, and went on to accumulate 24 career Tour titles. He also played an exceptionally busy schedule all over the world, and he has been called the world's most traveled athlete. Player has logged more than 26 million km (16 million mi) in air travel – in 2005 it was estimated that he had "probably flown further … than any athlete in history". Player has more victories than anyone else in the South African Open (13) and the Australian Open (7).
Since the engine was in development with Bloodlines and Valve's own Half-Life 2, Troika was working with unfamiliar code and tools, forcing it to write code to compensate for the unfinished engine and with only a single source of technical support. Troika developed a lighting system to create distinctive, moody illumination for the nighttime setting, a particle system for the special effects accompanying the vampire Disciplines, and a cloth system for clothing flow. Source lacked its later artificial intelligence (AI) coding, and Troika's code worked poorly with the Source engine.
== Biosynthesis == The apelin gene encodes a pre-proprotein of 77 amino acids, with a signal peptide in the N-terminal region. After translocation into the endoplasmic reticulum and cleavage of the signal peptide, the proprotein of 55 amino acids may generate several active fragments: a 36 amino acid peptide corresponding to the sequence 42-77 (apelin 36), a 17 amino acid peptide corresponding to the sequence 61-77 (apelin 17) and a 13 amino acid peptide corresponding to the sequence 65-77 (apelin 13). This latter fragment may also undergo a pyroglutamylation at the level of its N-terminal glutamine residue. However the presence and/or the concentrations of those peptides in human plasma has been questioned. Recently, 46 different apelin peptides ranging from apelin 55 (proapelin) to apelin 12 have been identified in bovine colostrum, including C-ter truncated isoforms.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.